Open AccessImatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam
Author(s) -
Hung Kien Do,
Van Quang Le,
Hoang Gia Nguyen,
Bich Phuong Nguyen Thi
Publication year - 2019
Publication title -
cancer control
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.794
H-Index - 72
ISSN - 1073-2748
DOI - 10.1177/1073274819863776
Subject(s) - medicine , imatinib mesylate , imatinib , vietnamese , gist , oncology , overall survival , stromal cell , stromal tumor , linguistics , philosophy , myeloid leukemia
Only limited data are available concerning the long-term outcomes of imatinib treatment among Vietnamese or Asian patients with unresectable or recurrent gastrointestinal stromal tumors (GISTs). Our study, which was conducted in 188 patients, aimed to assess the efficacy of imatinib mesylate against unresectable or recurrent GISTs. Imatinib had a high response rate and long survival. Some predictors favorable for progression-free survival and overall survival are good performance status and response with imatinib. Findings are discussed in relation to clinical practice in low- and middle-income country.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom